Oncolytics fast tracked for pancreatic cancer treatment

 FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.

https://finance.yahoo.com/news/oncolytics-biotech-receives-fda-fast-123200369.html